| Japanese |
|---|
| Title | 交感神経系腫瘍局在診断における131I-MIBGシンチグラフィの臨床的有用性の検討 - 多施設による臨床第III相試験報告 - |
|---|
| Subtitle | 原著 |
|---|
| Authors | 佐々木康人*1, 久保敦司*2, 日下部きよ子*3, 正木英一*4, 遠藤啓吾*5, 山下正人*6, 中條政敬*7, 金子昌生*8 |
|---|
| Authors(kana) | |
|---|
| Organization | *1東京大学医学部放射線科, *2慶應義塾大学医学部附属病院放射線科, *3東京女子医科大学放射線科, *4国立小児病院放射線科, *5群馬大学医学部核医学科, *6京都府立医科大学放射線科, *7鹿児島大学医学部放射線科, *8浜松医科大学放射線科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 29 |
|---|
| Number | 9 |
|---|
| Page | 1083-1098 |
|---|
| Year/Month | 1992/9 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」交感神経系腫瘍の局在診断における131I-MIBGの臨床的有用性の評価を目的として, 褐色細胞腫, 神経芽細胞腫, 甲状腺髄様癌などの患者66名を対象に第III相臨床試験を実施した. 施設担当医による症例記録より, 交感神経系腫瘍の有無が確認された150部位において集計したところ, 腫瘍が確認された72部位中61部位(84.7%)に本剤の異常集積を認め, 腫瘍が否定された78部位中74部位(94.9%)では異常集積を認めなかった. 陽性例の内訳は褐色細胞腫37部位中32部位(86.5%), 神経芽細胞腫28部位中22部位(78.6%), 甲状腺髄様癌6部位中6部位(100%)であった. 本剤の投与前後において臨床症状, 臨床検査値の変動を観察したが, 本剤の投与に起因すると思われる症状または臨床検査値の変化は認められなかった. 以上より, 本剤は交感神経系腫瘍の診断薬としてきわめて有用であると考えられた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 131I-MIBG scintigraphy, Pheochromocytoma, Neuroblastoma, Medullary carcinoma of the thyroid. |
|---|
| English |
|---|
| Title | The Assessment of Clinical Usefulness of 131I-MIBG Scintigraphy for Localization of Tumors of Sympathetic and Adrenomedullary Origin - A Report of Multicenter Phase III Clinical Trials - |
|---|
| Subtitle | |
|---|
| Authors | Yasuhito SASAKI*1, Atsushi KUBO*2, Kiyoko KUSAKABE*3, Hidekazu MASAKI*4, Keigo ENDO*5, Masato YAMASHITA*6, Masayuki NAKAJO*7, Masao KANEKO*8 |
|---|
| Authors(kana) | |
|---|
| Organization | *1Department of Radiology, Faculty of Medicine, The University of Tokyo, *2Department of Radiology, Keio University School of Medicine, *3Department of Radiology, Tokyo Women's Medical College, *4Department of Radiology, National Children's Hospital, *5Department of Nuclear Medicine, Gunma University School of Medicine, *6Department of Radiology, Kyoto Prefectural University of Medicine, *7Department of Radiology, Faculty of Medicine, Kagoshima University, *8Department of Radiology, Hamamatsu University School of Medicine |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 29 |
|---|
| Number | 9 |
|---|
| Page | 1083-1098 |
|---|
| Year/Month | 1992/9 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary]A phase III clinical study of 131I-metaiodobenzyl-guanidine (131I-MIBG) was performed in 66 patients with tumors of sympathetic and adrenomedullary origin, including 32 patients with suspected pheochromocytoma, 25 with suspected neuroblastoma, 7 pre- or postoperative medullary carcinoma of the thyroid and each with carcinoid and suspected Sipple's syndrome. A total of 150 sites which were confirmed for presence (72 sites) or absence (78 sites) of tumors were examined on 131I-MIBG scintigrams. True positive ratio of the scintigraphy was 84.7% (61/72) and true negative ratio was 94.9% (74/78). Positive scintigraphy was obtained in 86.5% (32/37) of pheochromocytoma, 78.6% (22/28) of neuroblastoma and 100% (6/6) of medullary carcinoma of the thyroid. Accumulation of 131I-MIBG was seen in 16.8% of normal adrenal glands. Neither adverse reactions nor abnormal laboratory findings were noted in relation to 131I-MIBG injections. Our study indicates that 131I-MIBG is a safe and clinically useful radiotracers for the visualization and localization of tumors of sympathetic and adrenomedullary origin. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 131I-MIBG scintigraphy, Pheochromocytoma, Neuroblastoma, Medullary carcinoma of the thyroid. |
|---|